Allogene Therapeutics Inc (ALLO)
5.025
-0.02
(-0.50%)
USD |
NASDAQ |
Mar 24, 16:00
5.025
0.00 (0.00%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 726.10M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -47.88% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2960.01 |
| Price to Book Value | 1.090 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
MT Newswires
03/21 07:32
Globe Newswire
03/14 17:30
Yahoo
03/07 09:55
Yahoo
03/06 09:35
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/04/2023* | 17:00 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 05/04/2023* | -- | Results | Q1 2023 | -- | -0.63 | -- | |
| 02/28/2023 | 17:00 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 02/28/2023 | -- | Results | Q4 2022 | -0.66 | -0.69 | 3.79% | |
| 11/02/2022 | 17:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/02/2022 | -- | Results | Q3 2022 | -0.58 | -0.65 | 10.87% | |
| 08/09/2022 | 17:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/09/2022 | -- | Results | Q2 2022 | -0.52 | -0.61 | 14.29% |
*Estimated Date/Time
Earnings
Profile
Edit
| Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies. |
| URL | https://www.allogene.com |
| Investor Relations URL | https://ir.allogene.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 04, 2023 (est.) |
| Last Earnings Release | Feb. 28, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 23, 2023.
Fundamentals
| Revenue (TTM) | 0.243M |
| Total Expenses (TTM) | 335.69M |
| Net Income (TTM) | -332.63M |
| Total Assets (Quarterly) | 817.08M |
| Total Liabilities (Quarterly) | 151.21M |
| Shareholders Equity (Quarterly) | 665.87M |
| Cash from Operations (TTM) | -220.52M |
| Cash from Investing (TTM) | 106.16M |
| Cash from Financing (TTM) | 2.95M |
Ratings
Profile
Edit
| Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies. |
| URL | https://www.allogene.com |
| Investor Relations URL | https://ir.allogene.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 04, 2023 (est.) |
| Last Earnings Release | Feb. 28, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| ALLO Tweets |